option chains Advertisement Fidelity
Home > Boards > US OTC > Medical - Drugs >

Advanced Cell Technology (ACTC)

ACTC RSS Feed
Add ACTC Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator locksflooring, sports guy, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 4/23/2014 6:49:59 PM - Followers: 599 - Board type: Free - Posts Today: 61

 
Advanced Cell Technology, Inc. (ACTC)

 

 

http://www.advancedcell.com

 

 

 

Company Headquarters:

Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406

Tel: (310) 576 0611
Fax: (310) 576 0662

info@advancedcell.com

 

Massachusetts Laboratory Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333


THE COMPANY:
 

Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company is currently conducting the only ongoing, FDA-cleared human embryonic stem cell (hESC)-based human clinical trials. The two trials, initiated in July 2011 at UCLA's Jules Stein Eye Institute, use retinal pigment epithelial (RPE) cells derived from hESCs to treat forms of macular degeneration. ACT also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. The company is also developing its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases, its Phase II-cleared Myoblast stem cell therapy for the treatment of chronic heart failure and other cardiac conditions, and other programs.

ACT's principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D.


PATENTS & INTELLECTUAL PROPERTY (IP):

ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine, and is positioning itself to have a dominant patent position around its stem cell-derived RPE program in leading markets around the world.
 
In 2010 ACT secured three far-reaching patents related to its RPE program, and more recently was issued the first patent for generating hemangioblast cells to treat a broad spectrum of vascular and hematopoietic disorders.
 
 
THERAPEUTIC PLATFORMS:

The company's RPE and HG programs are hESC-based, and its Myoblast program for cardiac disease is an adult autologous stem cell therapy. As documented in NATURE and Cell Stem Cell, ACT developed the "single-cell blastomere" technique, the first-ever proven alternative method for successful hESC generation without harm to the embryo, for which it was recently issued a broad patent
 
RPE Program - ACT has developed a fully-differentiated RPE cell derived from human embryonic stem cells, which can be used as a cellular therapy to treat retinal degenerative diseases. In July 2011 ACT initiated two Phase I/II clinical trials to test the safety of the therapy for Stargardt's Macular Dystrophy (SMD), and for Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD represents a $25-30 Billion market in the US and Europe alone, and there are no approved therapies currently available for either condition. Two patients have thus far been treated at UCLA, Institutional Review Board (IRB) approval for the SMD clinical trial has also been issued by Oregon Health & Science University (OHSU) and European regulatory clearance has been granted to initiate the first hESC trial in Europe.
Other recent milestones in ACT's RPE program include: the NIH proposed expanding its definition of hESCs for funding purposes, in part to accommodate ACT's lines derived using its patented "embryo-safe" single-cell blastomere technique; and both the FDA and the European Medicines Agency (EMA) granting ACT's RPE cells "Orphan" status for treatment of Stargardt's Disease.
 
Hemangioblast Program - ACT's Hemangioblast program is for the treatment of blood and cardiovascular diseases. A paper published in NATURE Methods revealed the company's successful generation of functional Hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.
 
Myoblast Program - ACT's Myoblast treatment may prove particularly beneficial for patients who have experienced a serious heart attack and are at risk for heart failure. ACT has secured FDA approval to commence with Phase II clinical trials. The Myoblast program has several advantages over currently-available approaches, including symptom management and disease modification.



Dr. Lanza explains some of the technology we are pursuing: http://www.youtube.com/watch?v=MPBiNlUFIww#t=55s


For more information visit www.AdvancedCell.com


Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001140098&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

Share Structure as of November 30, 2011:
 

Outstanding Shares
1,705,673,605

Reserved Shares
124,827,644

Authorized and Unreserved Shares

919,498,751

 

Authorized Preferred Shares

50,000,000

 

The following table sets forth information regarding beneficial ownership of our capital stock as of November 30, 2011 by:

·  5% or greater stockholders;
·  Each of our directors and named executive officers; and
·  All of our directors and executive officers, as a group.

 

Name and Address (1) of Beneficial Owner                                                                                         Common Stock Beneficially Owned                   Percentage of Shares Beneficially Owned 
5% or Greater Stockholders
None
Directors and Named Executive Officers
William M. Caldwell, IV**                                                                                                                             95,415,141 (1)                                                           5.58%%

Robert P. Lanza, M.D.                                                                                                                                  51,199,082 (2)                                                           2.97%%

Alan C. Shapiro                                                                                                                                           20,150,927 (3)                                                           1.18%%
Erkki Ruoslahti                                                                                                                                            2,500,000 (4)                                                                *
Gary Rabin                                                                                                                                                 23,087,430 (5)                                                           1.35%
Directors and Executive Officers as a Group (5 Persons)                                                                                192,352,580                                                               11.08%%

                                                                     

* Less than 1%

** Mr. Caldwell passed away on December 13, 2010

(1) Includes 5,108,546 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(2) Includes 17,583,207 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(3) Includes (i) 17,032,587 shares subject to convertible debentures, board fees, common stock grant held by The Shapiro Family Trust and of
which Dr. Shapiro may be deemed the beneficial owner, (ii) 3,018,340 shares subject to warrants in connection with the 2005-2008
convertible debentures, and (iii) 100,000 shares subject to stock options that are currently exercisable or exercisable within 60 days of
November 30, 2011.

(4) Includes 100,000 shares issuable upon exercise of options exercisable within 60 days of November 30, 2011. Effective August 1, 2011,
Erkki Ruoslahti resigned from the Board of Directors of the Company.

(5) Includes indirect ownership of (i) 1,239,501 shares issued to PDPI, LLC on December 22, 2010, upon exercise of certain warrants, which
such number of shares represents Mr. Rabin's proportional interest in the total number of shares held by PDPI, LLC, based on his 33.33%
equity interest in the entity. Mr. Rabin disclaims beneficial ownership in the shares held by PDPI, LLC, and (ii) 7,000,000 shares subject
to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

There are no arrangements known to the Company, including any pledge by any person of securities of the Company, the operation of
which may at a subsequent date result in a change in control of the Company.
 

Media Relations

Bill Douglass
Gotham Communications, LLC
(646)450-3615
bill [at] gothamcomm [dot] com

or

Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf [at] russopartnersllc [dot] com

Investor Relations

James Young
jyoung [at] ceocast [dot] com
(212) 732-4300

 

 

 

 

 


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

 

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ACTC
Current Price
Volume:
Bid Ask Day's Range
Wiki
ACTC News: Current Report Filing (8-k) 04/21/2014 04:33:29 PM
PostSubject
#65135   I'm happy to discuss the merits of any MightyLion 04/23/14 06:49:59 PM
#65134   Thanks Fairviewhill, that is probably the best and MightyLion 04/23/14 06:44:51 PM
#65133   No I didn't really add anything new today, MightyLion 04/23/14 06:40:04 PM
#65132   Damn.. good point, didn't think of that. MightyLion 04/23/14 06:37:21 PM
#65131   Fvh, how many times/day can you reiterate your north40000 04/23/14 05:52:41 PM
#65130   I wonder if something in the restatement of Fern Wood 04/23/14 04:24:13 PM
#65129   A professional's response given that this is a farviewhill 04/23/14 04:16:25 PM
#65128   i think A/G sit down is next week. guy3 04/23/14 04:06:56 PM
#65126   Wish I had some way to reassure you MightyLion 04/23/14 04:05:13 PM
#65125   You make assumptions. I listened to your concerns guy3 04/23/14 04:04:00 PM
#65124   Yeah sorting the wheat from the chaff can MightyLion 04/23/14 03:59:55 PM
#65123   I understand what you're saying. farviewhill 04/23/14 03:57:34 PM
#65122   farviewhill - agree not inappropriate. For me enough guy3 04/23/14 03:53:09 PM
#65121   ISON, I hear what you're saying, believe me farviewhill 04/23/14 03:52:09 PM
#65120   Reality is more painful at present. A simple MightyLion 04/23/14 03:49:04 PM
#65119   GUY, the old question again. 'are the posters farviewhill 04/23/14 03:46:06 PM
#65118   The creditor has a right to claim assets, MightyLion 04/23/14 03:42:36 PM
#65117   Well yeah, that's my point.. it's not a MightyLion 04/23/14 03:39:39 PM
#65116   WHICH IS MORE PAINFULL? watching PPS go down guy3 04/23/14 03:38:52 PM
#65115   You are exactly better expressing my dilemma in farviewhill 04/23/14 03:29:24 PM
#65114   It looks to me that too many individuals Vita 1 04/23/14 02:54:50 PM
#65113   This is just my opinion about all the guy3 04/23/14 02:46:34 PM
#65112   They are NOT going to lose their IP. art2426 04/23/14 02:45:04 PM
#65110   When all panic and run for exits, it art2426 04/23/14 02:33:30 PM
#65109   The amount of this default is less material MightyLion 04/23/14 02:30:43 PM
#65107   CHUCK, you're driving me nuts. Sure the science farviewhill 04/23/14 02:20:55 PM
#65106   T would like to believe that the company ison929 04/23/14 01:57:14 PM
#65105   Doesn't it? These MM's ACTC have are hideously ddls 04/23/14 01:54:45 PM
#65104   I agree with all your points, but I Cisco_Tajuara 04/23/14 01:52:37 PM
#65102   You never know, they may blow through the ddls 04/23/14 01:46:42 PM
#65101   Excuse my ignorance, as well, but I fail farviewhill 04/23/14 01:39:15 PM
#65099   I wonder if she sees good enough to ddls 04/23/14 01:31:01 PM
#65098   ACTC a Mismanaged Masterpiece Maxed ddls 04/23/14 01:12:02 PM
#65097   Excuse my ignorance, but are we talking about art2426 04/23/14 12:51:48 PM
#65096   ACTC/UCLA/PBS Stargardts patient giving her testimony about the chuckanutman 04/23/14 12:51:32 PM
#65095   For probably the first time ever, I have MightyLion 04/23/14 12:28:35 PM
#65093   Notice Of Default ddls 04/23/14 11:51:13 AM
#65092   It takes courage to defend Advanced Cell Technology's ddls 04/23/14 11:32:37 AM
#65091   Wondering how ACT will secure more funding with ddls 04/23/14 11:26:42 AM
#65090   Chuck, I especially appreciated your posting of the north40000 04/23/14 11:06:49 AM
#65089   I share your optimism. That will just be beninsac 04/23/14 11:02:05 AM
#65088   Green ACTC target .45 chuckanutman 04/23/14 10:35:55 AM
#65087   farviewhill I share your fears. Are you out? guy3 04/23/14 10:20:54 AM
#65085   One may ask themselves why they let Advanced ddls 04/23/14 09:49:31 AM
#65083   What's your point? That's already public information, so Cisco_Tajuara 04/23/14 09:31:35 AM
#65082   On April 15, 2014, Advanced Cell Technology, Inc. ddls 04/23/14 09:26:03 AM
#65081  Restored ACTC :) She is so wonderful, her courage chuckanutman 04/23/14 08:14:27 AM
#65080   It was amazing to hear Kathy talk about Fern Wood 04/23/14 08:05:14 AM
#65079   Transcript of Charlie rose show.. Dr Schwartz cty 04/23/14 07:57:21 AM
#65078   Green Day.... Fern Wood 04/23/14 07:46:12 AM
PostSubject